Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arthrolense, Baird Medical, Biolab, Pulse Biosciences, Smart Reporting, Terraplasma Medical, Waldemar Link.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Edge Medical, Neuraxix, Terumo.
With the number of beats Boston Science Corp. has posted in recent years, it could be auditioning as a heavy metal drummer. Third quarter results kept up the streak, with overall sales 2% ahead of consensus at $5.07 billion and earnings per share of 75 cents, 5% above the Street’s expectations. The company’s two market-transforming products, Watchman and Farapulse, led the strong across-the-board performance, which would be no surprise by now except when looking at the stunning growth rates and sales both posted in the same quarter last year.
It has been a positive year for med tech compared to previous years, said Antoine Papiernik, chairman and managing partner at Sofinnova Partners. The IPO market has reopened, several large financing deals have closed, and new players have entered the sector.
The Advanced Medical Technology Association has updated its code of ethics for interactions with health care professionals, which includes some much-needed updates that address both the burgeoning reliance on data and the increasing emphasis on the part of U.S. regulators on data security.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angiopro, Cormedix, Emboline, Euda Health, Inspira Technologies, Nauticus, Neurent Medical, Omed Health, Owlstone Medical, Profusa.
RSS
